PerturbAI is an AI-native therapeutics company that combines in vivo CRISPR perturbation with AI to map gene function and disease mechanisms in living organisms, and it says these causal maps are used to train models for drug discovery. Its initial focus is complex metabolic and chronic diseases, especially cardiometabolic disease, and it is positioning the platform to develop therapeutics for those markets. The company’s public launch centered on a world’s-largest in vivo CRISPR atlas generated from an 8 million-cell, brain-wide dataset, and its platform is described as combining CRISPR perturbations with single-nucleus RNA sequencing and causal AI models. Grace Zheng is identified as co-founder and CEO. PerturbAI said it closed an oversubscribed pre-seed round in Q3 2025. The company is based in San Francisco.
